NFSG
TVTX icon

Newbridge Financial Services Group’s Travere Therapeutics TVTX Stock Holding History

Newbridge Financial Services Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-70
Closed -$626 – 1330
2023
Q3 		$626 Hold
70
– – ﹤0.01% 1189
2023
Q2 		$1.07K Hold
70
– – ﹤0.01% 1208
2023
Q1 		$1.57K Hold
70
– – ﹤0.01% 1232
2022
Q4 		$1.47K Hold
70
– – ﹤0.01% 1264
2022
Q3 		$2K Hold
70
– – ﹤0.01% 1241
2022
Q2 		$2K Hold
70
– – ﹤0.01% 1226
2022
Q1 		$2K Hold
70
– – ﹤0.01% 1330
2021
Q4 		$2K Hold
70
– – ﹤0.01% 1282
2021
Q3 		$2K Hold
70
– – ﹤0.01% 1204
2021
Q2 		$1K Hold
70
– – ﹤0.01% 1400
2021
Q1 		$2K Buy
+70
New +$1.93K ﹤0.01% 1206

Other funds holding TVTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Newbridge Financial Services Group's TVTX Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 70 shares — an estimated $626 sold.

Newbridge Financial Services Group first reported a position in TVTX in Q1 2021 and held it in 11 quarters. The position peaked at $2K in Q3 2022. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 70 Travere Therapeutics shares in Q4 2023, an estimated $626.
  • Newbridge Financial Services Group first reported a position in Travere Therapeutics in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's Travere Therapeutics position peaked at $2K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.